{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:04:12Z","timestamp":1793210652005,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018707","name":"European Commission Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102400","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:55:39Z","timestamp":1759794939000},"page":"102400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-952X","authenticated-orcid":false,"given":"Justus","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz Therese","family":"Tony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Spieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klopfleisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias T.","family":"Rosenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-1369","authenticated-orcid":false,"given":"Thomas","family":"Nerreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102400_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","article-title":"Ror2 as a therapeutic target in cancer","volume":"150","author":"Debebe","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2025.102400_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tcb.2008.08.006","article-title":"Ror receptor tyrosine kinases: orphans no more","volume":"18","author":"Green","year":"2008","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102400_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1365-2443.2003.00662.x","article-title":"The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a\/JNK signalling pathway","volume":"8","author":"Oishi","year":"2003","journal-title":"Genes Cells"},{"key":"10.1016\/j.xcrm.2025.102400_bib4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1365-2443.2007.01128.x","article-title":"Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2","volume":"12","author":"Yamamoto","year":"2007","journal-title":"Genes Cells"},{"key":"10.1016\/j.xcrm.2025.102400_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116101","article-title":"Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma","volume":"9","author":"Rasmussen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102400_bib6","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1038\/onc.2009.116","article-title":"Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma","volume":"28","author":"Wright","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102400_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41375-019-0486-9","article-title":"The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation","volume":"34","author":"Frenquelli","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102400_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s004270100140","article-title":"Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development","volume":"211","author":"Al-Shawi","year":"2001","journal-title":"Dev. Genes Evol."},{"key":"10.1016\/j.xcrm.2025.102400_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/RRS-120018757","article-title":"Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans","volume":"23","author":"Yoda","year":"2003","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.celrep.2014.06.027","article-title":"Appropriate crypt formation in the uterus for embryo homing and implantation requires Wnt5a-ROR signaling","volume":"8","author":"Cha","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102400_bib11","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/pro.5560070718","article-title":"Identification of a Frizzled-like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases","volume":"7","author":"Saldanha","year":"1998","journal-title":"Protein Sci."},{"key":"10.1016\/j.xcrm.2025.102400_bib12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3892\/or.14.1.291","article-title":"Comparative genomics on ROR1 and ROR2 orthologs","volume":"14","author":"Katoh","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.xcrm.2025.102400_bib13","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1074\/jbc.RA120.012791","article-title":"Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications","volume":"295","author":"Goydel","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102400_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4161\/onci.20592","article-title":"A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)","volume":"1","author":"Stone","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102400_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Chang","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102400_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/path.3986","article-title":"ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour","volume":"227","author":"Edris","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2025.102400_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102400_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2022.281339","article-title":"All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Garc\u00eda-Guerrero","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102400_bib21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102400_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102559","article-title":"Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1","volume":"10","author":"John","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2025.102400_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102400_bib25","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.jmb.2017.08.003","article-title":"Mining Naive Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility","volume":"429","author":"Peng","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102400_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102400_bib29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102400_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12935-022-02816-3","article-title":"Clinical potential of PD-1\/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy","volume":"22","author":"Jahangir","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xcrm.2025.102400_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102400_bib34","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib36","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102400_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102400_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.xcrm.2025.102400_bib40","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102400_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib43","doi-asserted-by":"crossref","first-page":"TPS79","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79","article-title":"Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells","volume":"36","author":"Specht","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102400_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102400_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102400_bib47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41590-023-01498-x","article-title":"ST3GAL1 and betaII-spectrin pathways control CAR T cell migration to target tumors","volume":"24","author":"Hong","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102400_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib49","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nmeth.2224","article-title":"rapidSTORM: accurate, fast open-source software for localization microscopy","volume":"9","author":"Wolter","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102400_bib50","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102400_bib51","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1172\/JCI9177","article-title":"Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40\/CD40L interaction","volume":"105","author":"Lode","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102400_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102400_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.xcrm.2025.102400_bib55","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/bioinformatics\/btac160","article-title":"LOCAN: a python library for analyzing single-molecule localization microscopy data","volume":"38","author":"Doose","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102400_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12859-018-2435-4","article-title":"Single sample scoring of molecular phenotypes","volume":"19","author":"Foroutan","year":"2018","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102400_bib57","doi-asserted-by":"crossref","first-page":"D900","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: a cancer single-cell state atlas","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102400_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102400_bib60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:10:52Z","timestamp":1788563452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666379125004732"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102400","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102400"}}